Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Imaging Findings in Transgender Patients after Gender-affirming Surgery.

Stowell JT, Grimstad FW, Kirkpatrick DL, Brown ER, Santucci RA, Crane C, Patel AK, Phillips J, Ferreira MA, Ferreira FR, Ban AH, Baroni RH, Wu CC, Swan KA, Scott SA, Andresen KJ.

Radiographics. 2019 Sep-Oct;39(5):1368-1392. doi: 10.1148/rg.2019190010.

PMID:
31498743
2.

Multi-Drug/Gene NASH Therapy Delivery and Selective Hyperspectral NIR Imaging Using Chirality-Sorted Single-Walled Carbon Nanotubes.

Hasan MT, Campbell E, Sizova O, Lyle V, Akkaraju G, Kirkpatrick DL, Naumov AV.

Cancers (Basel). 2019 Aug 14;11(8). pii: E1175. doi: 10.3390/cancers11081175.

3.

Creating a Transgender-Inclusive Interventional Radiology Department.

Kirkpatrick DL, Stowell J, Grimstad F, Brown E, Fishback S, Lemons S.

J Vasc Interv Radiol. 2019 Jun;30(6):928-931. doi: 10.1016/j.jvir.2018.12.033. Epub 2019 Apr 5. Review.

PMID:
30956076
4.

Serving the Needs of Transgender and Gender-Diverse Persons in Radiology.

Stowell JT, Grimstad FW, Kirkpatrick DL, Brown LR, Flores EJ.

J Am Coll Radiol. 2019 Apr;16(4 Pt A):533-535. doi: 10.1016/j.jacr.2018.12.050. Epub 2019 Feb 26. No abstract available.

PMID:
30819454
5.

The Utility of a Benign Biliary Stricture Protocol in Preventing Symptomatic Recurrence and Surgical Revision.

Kirkpatrick DL, Hasham H, Collins Z, Johnson P, Lemons S, Shahzada H, Hunt SL, Walter C, Hill J, Fahrbach T.

J Vasc Interv Radiol. 2018 May;29(5):688-694. doi: 10.1016/j.jvir.2017.10.032. Epub 2018 Feb 15.

PMID:
29398411
6.

In vitro and in vivo assessment of the abuse potential of PF614, a novel BIO-MD™ prodrug of oxycodone.

Kirkpatrick DL, Schmidt WK, Morales R, Cremin J, Seroogy J, Husfeld C, Jenkins T.

J Opioid Manag. 2017 Jan/Feb;13(1):39-49. doi: 10.5055/jom.2017.0366.

PMID:
28345745
7.

Clinically Evaluated Cancer Drugs Inhibiting Redox Signaling.

Kirkpatrick DL, Powis G.

Antioxid Redox Signal. 2017 Feb 20;26(6):262-273. doi: 10.1089/ars.2016.6633. Epub 2016 Apr 22. Review.

8.

Seeding of the rectus sheath with hepatocellular carcinoma after image guided percutaneous liver biopsy using coaxial biopsy needle system.

Tchatalbachev VV, Kirkpatrick DL, Duff DJ, Travis MD.

J Radiol Case Rep. 2015 Jan 31;9(1):18-25. doi: 10.3941/jrcr.v9i1.1887. eCollection 2015 Jan.

9.

Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.

Bandari RP, Jiang Z, Reynolds TS, Bernskoetter NE, Szczodroski AF, Bassuner KJ, Kirkpatrick DL, Rold TL, Sieckman GL, Hoffman TJ, Connors JP, Smith CJ.

Nucl Med Biol. 2014 Apr;41(4):355-63. doi: 10.1016/j.nucmedbio.2014.01.001. Epub 2014 Jan 10.

10.

A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers.

Baker AF, Adab KN, Raghunand N, Chow H, Stratton SP, Squire SW, Boice M, Pestano LA, Kirkpatrick DL, Dragovich T.

Invest New Drugs. 2013 Jun;31(3):631-641. doi: 10.1007/s10637-012-9846-2. Epub 2012 Jun 19.

11.

Carbon Nanotubes: Solution for the Therapeutic Delivery of siRNA?

Kirkpatrick DL, Weiss M, Naumov A, Bartholomeusz G, Weisman RB, Gliko O.

Materials (Basel). 2012 Feb 13;5(2):278-301. doi: 10.3390/ma5020278.

12.

Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor.

Meuillet EJ, Zuohe S, Lemos R, Ihle N, Kingston J, Watkins R, Moses SA, Zhang S, Du-Cuny L, Herbst R, Jacoby JJ, Zhou LL, Ahad AM, Mash EA, Kirkpatrick DL, Powis G.

Mol Cancer Ther. 2010 Mar;9(3):706-17. doi: 10.1158/1535-7163.MCT-09-0985. Epub 2010 Mar 2.

13.

Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma.

Koul D, Shen R, Kim YW, Kondo Y, Lu Y, Bankson J, Ronen SM, Kirkpatrick DL, Powis G, Yung WK.

Neuro Oncol. 2010 Jun;12(6):559-69. doi: 10.1093/neuonc/nop058. Epub 2010 Feb 15.

14.

Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.

Ihle NT, Lemos R Jr, Wipf P, Yacoub A, Mitchell C, Siwak D, Mills GB, Dent P, Kirkpatrick DL, Powis G.

Cancer Res. 2009 Jan 1;69(1):143-50. doi: 10.1158/0008-5472.CAN-07-6656.

15.

Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha.

Koh MY, Spivak-Kroizman T, Venturini S, Welsh S, Williams RR, Kirkpatrick DL, Powis G.

Mol Cancer Ther. 2008 Jan;7(1):90-100. doi: 10.1158/1535-7163.MCT-07-0463.

16.

Utilization of distillers dried grains with solubles and phytase in sow lactation diets to meet the phosphorus requirement of the sow and reduce fecal phosphorus concentration.

Hill GM, Link JE, Rincker MJ, Kirkpatrick DL, Gibson ML, Karges K.

J Anim Sci. 2008 Jan;86(1):112-8. Epub 2007 Sep 18.

PMID:
17878284
17.

Thioredoxin signaling as a target for cancer therapy.

Powis G, Kirkpatrick DL.

Curr Opin Pharmacol. 2007 Aug;7(4):392-7. Epub 2007 Jul 3. Review.

PMID:
17611157
18.

A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors.

Ramanathan RK, Kirkpatrick DL, Belani CP, Friedland D, Green SB, Chow HH, Cordova CA, Stratton SP, Sharlow ER, Baker A, Dragovich T.

Clin Cancer Res. 2007 Apr 1;13(7):2109-14.

19.

Practicalities of drugging the phosphatidylinositol-3-kinase/Akt cell survival signaling pathway.

Powis G, Ihle N, Kirkpatrick DL.

Clin Cancer Res. 2006 May 15;12(10):2964-6. No abstract available.

20.

Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase.

Powis G, Wipf P, Lynch SM, Birmingham A, Kirkpatrick DL.

Mol Cancer Ther. 2006 Mar;5(3):630-6.

21.

The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma.

Baker AF, Dragovich T, Tate WR, Ramanathan RK, Roe D, Hsu CH, Kirkpatrick DL, Powis G.

J Lab Clin Med. 2006 Feb;147(2):83-90.

22.

The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts.

Ihle NT, Paine-Murrieta G, Berggren MI, Baker A, Tate WR, Wipf P, Abraham RT, Kirkpatrick DL, Powis G.

Mol Cancer Ther. 2005 Sep;4(9):1349-57.

23.
24.

Solubility, ionization, and partitioning behavior of unsymmetrical disulfide compounds: alkyl 2-imidazolyl disulfides.

Hashash A, Kirkpatrick DL, Lazo JS, Block LH.

J Pharm Sci. 2002 Jul;91(7):1686-92.

PMID:
12115830
25.

Normal-phase and stability-indicating reversed-phase high-performance liquid chromatographic methods for the determination of the novel antitumor agent: 1-methylpropyl-2-imidazolyldisulfide.

Hashash A, Kirkpatrick DL, Egorin MJ, Block LH, Lazo JS.

J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Mar 5;768(2):239-46.

PMID:
11888051
26.

Disruption of a single copy of the SERCA2 gene results in altered Ca2+ homeostasis and cardiomyocyte function.

Ji Y, Lalli MJ, Babu GJ, Xu Y, Kirkpatrick DL, Liu LH, Chiamvimonvat N, Walsh RA, Shull GE, Periasamy M.

J Biol Chem. 2000 Dec 1;275(48):38073-80.

27.

Transgenic overexpression of constitutively active protein kinase C epsilon causes concentric cardiac hypertrophy.

Takeishi Y, Ping P, Bolli R, Kirkpatrick DL, Hoit BD, Walsh RA.

Circ Res. 2000 Jun 23;86(12):1218-23.

PMID:
10864911
28.

Parallel syntheses of disulfide inhibitors of the thioredoxin redox system as potential antitumor agents.

Kirkpatrick DL, Watson S, Kunkel M, Fletcher S, Ulhaq S, Powis G.

Anticancer Drug Des. 1999 Oct;14(5):421-32.

PMID:
10766297
29.

Alterations in Ca2+ cycling proteins and G alpha q signaling after left ventricular assist device support in failing human hearts.

Takeishi Y, Jalili T, Hoit BD, Kirkpatrick DL, Wagoner LE, Abraham WT, Walsh RA.

Cardiovasc Res. 2000 Mar;45(4):883-8.

PMID:
10728414
30.

Structure-based drug design: combinatorial chemistry and molecular modeling.

Kirkpatrick DL, Watson S, Ulhaq S.

Comb Chem High Throughput Screen. 1999 Aug;2(4):211-21. Review.

PMID:
10469881
31.

Effect of angiotensin-converting enzyme inhibition on protein kinase C and SR proteins in heart failure.

Takeishi Y, Bhagwat A, Ball NA, Kirkpatrick DL, Periasamy M, Walsh RA.

Am J Physiol. 1999 Jan;276(1):H53-62. doi: 10.1152/ajpheart.1999.276.1.H53.

PMID:
9887017
32.

Enhanced myocardial contractility and increased Ca2+ transport function in transgenic hearts expressing the fast-twitch skeletal muscle sarcoplasmic reticulum Ca2+-ATPase.

Loukianov E, Ji Y, Grupp IL, Kirkpatrick DL, Baker DL, Loukianova T, Grupp G, Lytton J, Walsh RA, Periasamy M.

Circ Res. 1998 Nov 2;83(9):889-97.

PMID:
9797337
33.

Thioredoxin redox control of cell growth and death and the effects of inhibitors.

Powis G, Kirkpatrick DL, Angulo M, Baker A.

Chem Biol Interact. 1998 Apr 24;111-112:23-34. Review.

PMID:
9679540
34.

Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides.

Kirkpatrick DL, Kuperus M, Dowdeswell M, Potier N, Donald LJ, Kunkel M, Berggren M, Angulo M, Powis G.

Biochem Pharmacol. 1998 Apr 1;55(7):987-94.

PMID:
9605422
35.

Effects of total replacement of atrial myosin light chain-2 with the ventricular isoform in atrial myocytes of transgenic mice.

Pawloski-Dahm CM, Song G, Kirkpatrick DL, Palermo J, Gulick J, Dorn GW 2nd, Robbins J, Walsh RA.

Circulation. 1998 Apr 21;97(15):1508-13.

PMID:
9576432
36.

Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs.

Kunkel MW, Kirkpatrick DL, Johnson JI, Powis G.

Anticancer Drug Des. 1997 Dec;12(8):659-70.

PMID:
9448705
37.

Redox active disulfides: the thioredoxin system as a drug target.

Kirkpatrick DL, Ehrmantraut G, Stettner S, Kunkel M, Powis G.

Oncol Res. 1997;9(6-7):351-6.

PMID:
9406241
38.

Selenium and the thioredoxin redox system: effects on cell growth and death.

Powis G, Gasdaska JR, Gasdaska PY, Berggren M, Kirkpatrick DL, Engman L, Cotgreave IA, Angulo M, Baker A.

Oncol Res. 1997;9(6-7):303-12. Review.

PMID:
9406236
39.

Oxidative inactivation of thioredoxin as a cellular growth factor and protection by a Cys73-->Ser mutation.

Gasdaska JR, Kirkpatrick DL, Montfort W, Kuperus M, Hill SR, Berggren M, Powis G.

Biochem Pharmacol. 1996 Dec 13;52(11):1741-7.

PMID:
8986137
40.

Synthesis and bioreductive potential of a mono N-oxide derivative of the alkylating agent chlorambucil.

Kirkpatrick DL, Schroeder HL, Chandler KJ.

Anticancer Drugs. 1994 Aug;5(4):467-72.

PMID:
7949253
41.

Promoting top employees to supervisor may be a dangerous leap of faith.

Kirkpatrick DL.

Healthc Hum Resour. 1994 May;3(5):9-11. No abstract available.

PMID:
10135982
42.

High-performance liquid chromatographic method for the separation of chlorambucil and its N-oxide prodrug.

Chandler KJ, McCabe JB, Kirkpatrick DL.

J Chromatogr. 1994 Feb 11;652(2):195-202.

PMID:
8006104
43.

Reversible inhibition of human thioredoxin reductase activity by cytotoxic alkyl 2-imidazolyl disulfide analogues.

Oblong JE, Chantler EL, Gallegos A, Kirkpatrick DL, Chen T, Marshall N, Powis G.

Cancer Chemother Pharmacol. 1994;34(5):434-8.

PMID:
8070012
44.

Disulfide cytotoxicity under hypoxia.

Kirkpatrick DL, Sa'da IA, Chernoff W, Kuperus M.

Oncol Res. 1994;6(10-11):545-52.

PMID:
7620224
45.

The thioredoxin/thioredoxin reductase redox system and control of cell growth.

Powis G, Oblong JE, Gasdaska PY, Berggren M, Hill SR, Kirkpatrick DL.

Oncol Res. 1994;6(10-11):539-44.

PMID:
7620223
46.

Effect of a hypoxic tumor cell cytotoxic disulfide on the membrane and DNA of tumor cells in culture.

Kirkpatrick DL, King KM, Abu Sa'da I, Kelln RA, Richardson ME, Siemann DW.

Anticancer Drugs. 1992 Dec;3(6):651-8.

PMID:
1337706
47.

Synthesis and cytotoxic evaluation of some 6-arylidene-2-(alpha-hydroxyamino-alpha-arylmethyl)cyclohexanone oximes and related compounds.

Dimmock JR, Sidhu KK, Quail JW, Jia Z, Duffy MJ, Reid RS, Kirkpatrick DL, Zhu L, Fletcher SM.

J Pharm Sci. 1992 Nov;81(11):1059-64.

PMID:
1447704
48.

Modification of the DiSC assay by the incorporation of monoclonal antibody staining.

Kirkpatrick DL, Chen L, Goh TS.

Leuk Res. 1992 Nov;16(11):1097-103.

PMID:
1434746
49.

Cytotoxicity of Mannich bases of alpha-arylidene-beta-ketoesters and related compounds against EMT6 mammary carcinoma cells.

Dimmock JR, Erciyas E, Bigam GE, Kirkpatrick DL, Duke MM.

Drug Des Deliv. 1990 Dec;7(1):51-8.

PMID:
2096834
50.

Evaluation of the cytotoxicity of some Mannich bases of acetophenone against the EMT6 tumour.

Dimmock JR, Erciyas E, Raghavan SK, Kirkpatrick DL.

Pharmazie. 1990 Oct;45(10):755-7.

PMID:
2089386

Supplemental Content

Loading ...
Support Center